637 related articles for article (PubMed ID: 22674529)
21. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer.
Wang L; Wu S; Ou G; Bi N; Li W; Ren H; Cao J; Liang J; Li J; Zhou Z; Lv J; Zhang X
Lung Cancer; 2012 Jul; 77(1):89-96. PubMed ID: 22418243
[TBL] [Abstract][Full Text] [Related]
22. Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung.
Suntharalingam M; Paulus R; Edelman MJ; Krasna M; Burrows W; Gore E; Wilson LD; Choy H
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):456-63. PubMed ID: 22543206
[TBL] [Abstract][Full Text] [Related]
23. [Weekly paclitaxel and carboplatin with concurrent three dimensional conformal radiotherapy for locally advanced non small cell lung cancer].
Wang J; Pang QS; Wang P; Wang J; Wang W
Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):769-72. PubMed ID: 18396691
[TBL] [Abstract][Full Text] [Related]
24. A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by weekly paclitaxel or observation for patients with locally advanced inoperable non-small-cell lung cancer.
Carter DL; Garfield D; Hathorn J; Mundis R; Boehm KA; Ilegbodu D; Asmar L; Reynolds C
Clin Lung Cancer; 2012 May; 13(3):205-13. PubMed ID: 22138037
[TBL] [Abstract][Full Text] [Related]
25. Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival.
Gielda BT; Mehta P; Khan A; Marsh JC; Zusag TW; Warren WH; Fidler MJ; Abrams RA; Bonomi P; Liptay M; Faber LP
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):985-91. PubMed ID: 20932684
[TBL] [Abstract][Full Text] [Related]
26. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
[TBL] [Abstract][Full Text] [Related]
27. Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study.
Wirth LJ; Lucca J; Ostler P; Fidias P; Lynch C; Jänne PA; Herbst RS; Johnson BE; Sugarbaker DJ; Mathisen DJ; Lukanich JM; Choi NC; Berman SM; Skarin AT
Clin Cancer Res; 2003 May; 9(5):1698-704. PubMed ID: 12738723
[TBL] [Abstract][Full Text] [Related]
28. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
[TBL] [Abstract][Full Text] [Related]
29. Results of multifield conformal radiation therapy of nonsmall-cell lung carcinoma using multileaf collimation beams.
Bahri S; Flickinger JC; Kalend AM; Deutsch M; Belani CP; Sciurba FC; Luketich JD; Greenberger JS
Radiat Oncol Investig; 1999; 7(5):297-308. PubMed ID: 10580899
[TBL] [Abstract][Full Text] [Related]
30. Weekly docetaxel and cisplatin with concomitant radiotherapy in addition to surgery and/or consolidation chemotherapy in stage III non-small cell lung cancer.
Sen F; Saglam EK; Toker A; Dilege S; Kizir A; Oral EN; Saip P; Sakallioglu B; Topuz E; Aydiner A
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1497-505. PubMed ID: 21499895
[TBL] [Abstract][Full Text] [Related]
31. Twelve-year follow-up of trimodality therapy for stage IIIA non-small cell lung cancer.
Weitberg AB; Liu L; Yashar J; Glicksman AS
J Exp Clin Cancer Res; 2001 Sep; 20(3):335-40. PubMed ID: 11718211
[TBL] [Abstract][Full Text] [Related]
32. Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer.
Park SH; Choi SJ; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Cho EK; Shin DB; Hoon Lee J
Cancer; 2007 Feb; 109(4):732-40. PubMed ID: 17211861
[TBL] [Abstract][Full Text] [Related]
33. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450).
De Ruysscher D; Wanders R; van Baardwijk A; Dingemans AM; Reymen B; Houben R; Bootsma G; Pitz C; van Eijsden L; Geraedts W; Baumert BG; Lambin P
J Thorac Oncol; 2012 Oct; 7(10):1547-55. PubMed ID: 22982655
[TBL] [Abstract][Full Text] [Related]
34. Proton therapy with concurrent chemotherapy for non-small-cell lung cancer: technique and early results.
Hoppe BS; Flampouri S; Henderson RH; Pham D; Bajwa AA; D'Agostino H; Huh SN; Li Z; Mendenhall NP; Nichols RC
Clin Lung Cancer; 2012 Sep; 13(5):352-8. PubMed ID: 22264659
[TBL] [Abstract][Full Text] [Related]
35. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
Scagliotti G; Novello S; von Pawel J; Reck M; Pereira JR; Thomas M; Abrão Miziara JE; Balint B; De Marinis F; Keller A; Arén O; Csollak M; Albert I; Barrios CH; Grossi F; Krzakowski M; Cupit L; Cihon F; Dimatteo S; Hanna N
J Clin Oncol; 2010 Apr; 28(11):1835-42. PubMed ID: 20212250
[TBL] [Abstract][Full Text] [Related]
36. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.
Pless M; Stupp R; Ris HB; Stahel RA; Weder W; Thierstein S; Gerard MA; Xyrafas A; Früh M; Cathomas R; Zippelius A; Roth A; Bijelovic M; Ochsenbein A; Meier UR; Mamot C; Rauch D; Gautschi O; Betticher DC; Mirimanoff RO; Peters S;
Lancet; 2015 Sep; 386(9998):1049-56. PubMed ID: 26275735
[TBL] [Abstract][Full Text] [Related]
37. Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study).
Moro-Sibilot D; Audigier-Valette C; Merle P; Quoix E; Souquet PJ; Barlesi F; Chouaid C; Molinier O; Bennouna J; Lavolé A; Mazières J; Toffart AC; Langlais A; Morin F; Zalcman G
Lung Cancer; 2015 Aug; 89(2):139-45. PubMed ID: 26059274
[TBL] [Abstract][Full Text] [Related]
38. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
Lara PN; Douillard JY; Nakagawa K; von Pawel J; McKeage MJ; Albert I; Losonczy G; Reck M; Heo DS; Fan X; Fandi A; Scagliotti G
J Clin Oncol; 2011 Aug; 29(22):2965-71. PubMed ID: 21709202
[TBL] [Abstract][Full Text] [Related]
39. Long-term follow-up of phase II trial of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer.
Tokuda Y; Takigawa N; Kozuki T; Kamei H; Bessho A; Tada A; Hotta K; Katsui K; Kanazawa S; Tanimoto M; Kiura K
Acta Oncol; 2012 Apr; 51(4):537-40. PubMed ID: 22085375
[TBL] [Abstract][Full Text] [Related]
40. Induction combination chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer.
Herse B; Dalichau H; Wörmann B; Hemmerlein B; Schmidberger H; Hess CF; Hannemann P; Criée CP; Hiddemann W; Griesinger F
Thorac Cardiovasc Surg; 1998 Oct; 46(5):298-302. PubMed ID: 9885122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]